Skip to content ↓

Topic

Bioengineering and biotechnology

Download RSS feed: News Articles / In the Media / Audio

Displaying 31 - 45 of 175 news clips related to this topic.
Show:

CNBC

CNBC reporter Catherine Clifford spotlights C16 Biosciences, a startup co-founded by MIT alumni that is developing a palm oil alternative called Palmless. “What we are building is a platform technology that can produce all different kinds of microbial oils,” explains David Heller ’18, co-founder and head of operations at C16 Biosciences. “It’s definitely possible that we’re able to make other kinds of vegetable oil replacements in the future.” 

Boston Business Journal

Landmark Bio, a cell and gene therapy manufacturing company co-founded by MIT and a number of other institutions, is focused on accelerating access to innovative therapies for patients, reports Rowan Walrath for Boston Business Journal. "Landmark's new facility includes laboratory space for research and early-stage drug development, as well as analytics tools,” writes Walrath. 

The Boston Globe

MIT and a number of other local institutions have launched Landmark Bio, a cell and gene therapy manufacturing firm aimed at helping small startups develop experimental therapies that are reliable, consistent, and large enough to be used in clinical trials, reports Ryan Cross for The Boston Globe.

The Washington Post

Washington Post reporter Pranshu Verma writes about how Prof. Dina Katabi and her colleagues developed a new AI tool that could be used to help detect early signs of Parkinson’s by analyzing a patient’s breathing patterns. For diseases like Parkinson’s “one of the biggest challenges is that we need to get to [it] very early on, before the damage has mostly happened in the brain,” said Katabi. “So being able to detect Parkinson’s early is essential.”

Forbes

Forbes contributor Jennifer Kite-Powell spotlights how MIT researchers created a new AI system that analyzes radio waves bouncing off a person while they sleep to monitor breathing patterns and help identify Parkinson’s disease. “The device can also measure how bad the disease has become and could be used to track Parkinson's progression over time,” writes Kite-Powell.

The Boston Globe

A new tool for diagnosing Parkinson’s disease developed by MIT researchers uses an AI system to monitor a person’s breathing patterns during sleep, reports Hiawatha Bray for The Boston Globe. “The system is capable of detecting the chest movements of a sleeping person, even if they’re under a blanket or lying on their side,” writes Bray. “It uses software to filter out all other extraneous information, until only the breathing data remains. Using it for just one night provides enough data for a diagnosis.”

WBUR

Boston Globe reporter Hiawatha Bray speaks with Radio Boston host Tiziana Dearing about how MIT researchers developed an artificial intelligence model that uses a person’s breathing patterns to detect Parkinson’s Disease. The researchers “hope to continue doing this for other diseases like Alzheimer’s and potentially other neurological diseases,” says Bray.

Fierce Biotech

Researchers at MIT have developed an artificial intelligence sensor that can track the progression of Parkinson’s disease in patients based on their breathing while they sleep, reports Conor Hale for Fierce Biotech. “The device emits radio waves and captures their reflection to read small changes in its immediate environment,” writes Hale. “It works like a radar, but in this case, the device senses the rise and fall of a person’s chest.”

Boston.com

MIT researchers have developed a new artificial intelligence system that uses a person’s breathing pattern to help detect Parkinson’s sisease, reports Susannah Sudborough for Boston.com. “The device emits radio signals, analyzes reflections off the surrounding environment, and monitors the person’s breathing patterns without any bodily contact,” writes Sudborough.

STAT

Researchers at MIT and other institutions have developed an artificial intelligence tool that can analyze changes in nighttime breathing to detect and track the progression of Parkinson’s disease, reports Casey Ross for STAT. “The AI was able to accurately flag Parkinson’s using one night of breathing data collected from a belt worn around the abdomen or from a passive monitoring system that tracks breathing using a low-power radio signal,” writes Ross.

The Conversation

The Conversation spotlights Institute Prof. Robert Langer ‘74 who spoke at the 2022 Imagine Solutions Conference about his academic career and work applying his chemical engineering background to his research in health sciences. “I learned that if you’re not your own champion, nobody else will be,” says Langer. “So, I got involved in patenting things, and my students were very interested in seeing their work make a difference… My story is sort of one person’s example of how you can try to use science to help relieve suffering and prolong life.”

The Boston Globe

Boston Globe reporter David Abel spotlights the Mice Against Ticks project, which is aimed at preventing tick-borne diseases such as Lyme disease through immunizing mice.  “With so many people suffering from Lyme every single day, which is an awful disease, we need a solution urgently,” explains graduate student and Mice Against Ticks research director Joanna Buchthal. “This offers a real, if revolutionary, way to tackle the problem.”

The Boston Globe

Satellite Bio, a startup co-founded by Prof. Sangeeta Bhatia, aims to create “tissue implants to ‘repair, restore, or even replace’ diseased or dying organs,” reports Ryan Cross for The Boston Globe.

TechCrunch

MIT startup Volta Labs is developing a new instrument that can automate the processes used to prepare genetic samples, reports Emma Betuel for TechCrunch. CEO and co-founder Udayan Umapathi ’17 is confident that with the right programming, the platform could allow “liquids to be manipulated in even more complex ways, like using magnetic fields to draw certain molecules out of samples for further analysis,” writes Betuel.

Forbes

David Lucchino ’06 and Prof. Robert Langer have co-founded Frequency Therapeutics, a biotechnology company focused on developing a new approach to restoring hearing from the most common form of hearing loss, reports Jack Kelly for Forbes. “FX-322 is designed to treat the underlying cause of SNHL (sensorineural hearing loss) by regenerating sensory hair cells through activation of progenitor cells already present in the cochlea,” writes Kelly.